tiprankstipranks
Trending News
More News >

CalciMedica Stockholders Approve Equity Plan Amendment

Story Highlights
CalciMedica Stockholders Approve Equity Plan Amendment

Don’t Miss TipRanks’ Half-Year Sale

An update from CalciMedica ( (CALC) ) is now available.

On June 24, 2025, CalciMedica, Inc. held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the company’s 2023 Equity Incentive Plan, increasing the number of shares authorized for issuance by 600,000. Additionally, stockholders elected three Class I directors to serve until 2028 and ratified the appointment of Baker Tilly US, LLP as the company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CALC) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CalciMedica stock, see the CALC Stock Forecast page.

Spark’s Take on CALC Stock

According to Spark, TipRanks’ AI Analyst, CALC is a Underperform.

CalciMedica’s low stock score reflects its financial challenges, including zero revenue and negative cash flows. However, technical indicators suggest the stock is currently oversold, providing a potential entry point for risk-tolerant investors. The promising results from the Auxora trial offer a positive outlook, potentially improving future financial performance.

To see Spark’s full report on CALC stock, click here.

More about CalciMedica

Average Trading Volume: 26,445

Technical Sentiment Signal: Sell

Current Market Cap: $21.94M

Learn more about CALC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1